Publication number: 20240228535
Abstract: The present invention provides a compound of Formula I wherein R1, R2, R3, R4, R5, R6, R7, and subscripts x and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.
Type:
Application
Filed:
November 20, 2023
Publication date:
July 11, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
John J. Acton, III, Mayuri Gupta, Michael J. Kelly, III, Franca-Maria Klingler, Mark Eric Layton, John A. McCauley, Gregori J. Morriello, Christopher Charles Nawrat, Craig A. Parish, Anthony J. Roecker, Manuel de Lera Ruiz, Jing Su, Valerie W. Shurtleff, Quang T. Truong